Are 0 3 0 3 O
currently 4 13 4 13 O
receiving 14 23 14 23 O
an 24 26 24 26 O
investigational 27 42 27 42 B-treatment
drug 43 47 43 47 I-treatment
in 48 50 48 50 I-treatment
a 51 52 51 52 I-treatment
clinical 53 61 53 61 I-treatment
trial 62 67 62 67 I-treatment
or 68 70 68 70 O
participating 71 84 71 84 O
in 85 87 85 87 O
any 88 91 88 91 B-treatment
other 92 97 92 97 I-treatment
type 98 102 98 102 I-treatment
of 103 105 103 105 I-treatment
medical 106 113 106 113 I-treatment
research 114 122 114 122 I-treatment
judged 123 129 123 129 O
not 130 133 130 133 O
to 134 136 134 136 O
be 137 139 137 139 O
scientifically 140 154 140 154 O
or 155 157 155 157 O
medically 158 167 158 167 O
compatible 168 178 168 178 O
with 179 183 179 183 O
this 184 188 184 188 O
study 189 194 189 194 O

Have 0 4 195 199 O
a 5 6 200 201 O
diagnosis 7 16 202 211 O
of 17 19 212 214 O
HR+ 20 23 215 218 B-cancer
, 23 24 218 219 O
HER2- 25 30 220 225 B-cancer
breast 31 37 226 232 I-cancer
cancer 38 44 233 239 I-cancer

Have 0 4 240 244 O
a 5 6 245 246 O
negative 7 15 247 255 B-pregnancy
serum 16 21 256 261 I-pregnancy
pregnancy 22 31 262 271 I-pregnancy
test 32 36 272 276 O
at 37 39 277 279 O
baseline 40 48 280 288 O
( 49 50 289 290 O
within 50 56 290 296 O
14 57 59 297 299 B-upper_bound
days 60 64 300 304 I-upper_bound
prior 65 70 305 310 I-upper_bound
to 71 73 311 313 O
randomization 74 87 314 327 O
) 87 88 327 328 O
and 89 92 329 332 O
agree 93 98 333 338 B-contraception_consent
to 99 101 339 341 I-contraception_consent
use 102 105 342 345 I-contraception_consent
medically 106 115 346 355 I-contraception_consent
approved 116 124 356 364 I-contraception_consent
precautions 125 136 365 376 I-contraception_consent
to 137 139 377 379 O
prevent 140 147 380 387 O
pregnancy 148 157 388 397 O
during 158 164 398 404 O
the 165 168 405 408 O
study 169 174 409 414 O
and 175 178 415 418 O
for 179 182 419 422 O
12 183 185 423 425 B-upper_bound
weeks 186 191 426 431 I-upper_bound
following 192 201 432 441 O
the 202 205 442 445 O
last 206 210 446 450 O
dose 211 215 451 455 O
of 216 218 456 458 O
abemaciclib 219 230 459 470 B-treatment
if 231 233 471 473 O
postmenopausal 234 248 474 488 O
status 249 255 489 495 O
is 256 258 496 498 O
due 259 262 499 502 O
to 263 265 503 505 O
ovarian 266 273 506 513 O
suppression 274 285 514 525 O
with 286 290 526 530 O
a 291 292 531 532 O
GnRH 293 297 533 537 B-treatment
agonist 298 305 538 545 I-treatment

Have 0 4 546 550 O
a 5 6 551 552 O
performance 7 18 553 564 O
status 19 25 565 571 O
≤1 26 28 572 574 O
on 29 31 575 577 O
the 32 35 578 581 O
ECOG 36 40 582 586 B-clinical_variable
scale 41 46 587 592 O

Have 0 4 593 597 O
a 5 6 598 599 O
personal 7 15 600 608 O
history 16 23 609 616 O
within 24 30 617 623 O
the 31 34 624 627 O
last 35 39 628 632 B-upper_bound
12 40 42 633 635 I-upper_bound
months 43 49 636 642 I-upper_bound
of 50 52 643 645 O
any 53 56 646 649 O
of 57 59 650 652 O
the 60 63 653 656 O
following 64 73 657 666 O
conditions 74 84 667 677 O
: 84 85 677 678 O
syncope 86 93 679 686 O
of 94 96 687 689 O
cardiovascular 97 111 690 704 B-chronic_disease
etiology 112 120 705 713 I-chronic_disease
, 120 121 713 714 O
ventricular 122 133 715 726 B-chronic_disease
tachycardia 134 145 727 738 I-chronic_disease
, 145 146 738 739 O
ventricular 147 158 740 751 B-chronic_disease
fibrillation 159 171 752 764 I-chronic_disease
, 171 172 764 765 O
or 173 175 766 768 O
sudden 176 182 769 775 O
cardiac 183 190 776 783 O
arrest 191 197 784 790 O

Have 0 4 791 795 O
active 5 11 796 802 O
bacterial 12 21 803 812 B-chronic_disease
or 22 24 813 815 O
fungal 25 31 816 822 B-chronic_disease
infection 32 41 823 832 I-chronic_disease
, 41 42 832 833 O
or 43 45 834 836 O
detectable 46 56 837 847 O
viral 57 62 848 853 B-chronic_disease
infection 63 72 854 863 I-chronic_disease

Have 0 4 864 868 O
clinical 5 13 869 877 O
evidence 14 22 878 886 O
or 23 25 887 889 O
history 26 33 890 897 O
of 34 36 898 900 O
central 37 44 901 908 B-cancer
nervous 45 52 909 916 I-cancer
system 53 59 917 923 I-cancer
metastasis 60 70 924 934 I-cancer

Have 0 4 935 939 O
discontinued 5 17 940 952 O
previous 18 26 953 961 B-treatment
therapies 27 36 962 971 I-treatment
for 37 40 972 975 O
cancer 41 47 976 982 B-cancer
( 48 49 983 984 O
including 49 58 984 993 O
specifically 59 71 994 1006 O
, 71 72 1006 1007 O
aromatase 73 82 1008 1017 B-treatment
inhibitors 83 93 1018 1028 I-treatment
, 93 94 1028 1029 O
anti 95 99 1030 1034 B-treatment
- 99 100 1034 1035 I-treatment
estrogens 100 109 1035 1044 I-treatment
, 109 110 1044 1045 O
chemotherapy 111 123 1046 1058 B-treatment
, 123 124 1058 1059 O
radiotherapy 125 137 1060 1072 B-treatment
, 137 138 1072 1073 O
and 139 142 1074 1077 O
immunotherapy 143 156 1078 1091 B-treatment
) 156 157 1091 1092 O
for 158 161 1093 1096 O
at 162 164 1097 1099 O
least 165 170 1100 1105 O
21 171 173 1106 1108 B-lower_bound
days 174 178 1109 1113 I-lower_bound
for 179 182 1114 1117 O
myelosuppressive 183 199 1118 1134 B-treatment
agents 200 206 1135 1141 I-treatment
or 207 209 1142 1144 O
14 210 212 1145 1147 B-lower_bound
days 213 217 1148 1152 I-lower_bound
for 218 221 1153 1156 O
nonmyelosuppressive 222 241 1157 1176 B-treatment
agents 242 248 1177 1183 I-treatment
prior 249 254 1184 1189 O
to 255 257 1190 1192 O
receiving 258 267 1193 1202 O
study 268 273 1203 1208 B-treatment
drug 274 278 1209 1213 I-treatment
, 278 279 1213 1214 O
and 280 283 1215 1218 O
recovered 284 293 1219 1228 O
from 294 298 1229 1233 O
the 299 302 1234 1237 O
acute 303 308 1238 1243 O
effects 309 316 1244 1251 O
of 317 319 1252 1254 O
therapy 320 327 1255 1262 O
( 328 329 1263 1264 O
until 329 334 1264 1269 O
the 335 338 1270 1273 O
toxicity 339 347 1274 1282 O
resolves 348 356 1283 1291 O
to 357 359 1292 1294 O
either 360 366 1295 1301 O
baseline 367 375 1302 1310 O
or 376 378 1311 1313 O
at 379 381 1314 1316 O
least 382 387 1317 1322 O
Grade 388 393 1323 1328 O
1 394 395 1329 1330 O
) 395 396 1330 1331 O
except 397 403 1332 1338 O
for 404 407 1339 1342 O
residual 408 416 1343 1351 B-chronic_disease
alopecia 417 425 1352 1360 I-chronic_disease
or 426 428 1361 1363 O
peripheral 429 439 1364 1374 B-chronic_disease
neuropathy 440 450 1375 1385 I-chronic_disease

Have 0 4 1386 1390 O
had 5 8 1391 1394 O
major 9 14 1395 1400 B-treatment
surgery 15 22 1401 1408 I-treatment
within 23 29 1409 1415 O
14 30 32 1416 1418 B-upper_bound
days 33 37 1419 1423 I-upper_bound
prior 38 43 1424 1429 I-upper_bound
to 44 46 1430 1432 O
randomization 47 60 1433 1446 O
of 61 63 1447 1449 O
study 64 69 1450 1455 B-treatment
drug 70 74 1456 1460 I-treatment
to 75 77 1461 1463 O
allow 78 83 1464 1469 O
for 84 87 1470 1473 O
post 88 92 1474 1478 O
- 92 93 1478 1479 O
operative 93 102 1479 1488 O
healing 103 110 1489 1496 O
of 111 113 1497 1499 O
the 114 117 1500 1503 O
surgical 118 126 1504 1512 O
wound 127 132 1513 1518 O
and 133 136 1519 1522 O
site(s 137 143 1523 1529 O
) 143 144 1529 1530 O

Have 0 4 1531 1535 O
inflammatory 5 17 1536 1548 O
breast 18 24 1549 1555 B-cancer
cancer 25 31 1556 1562 I-cancer
or 32 34 1563 1565 O
a 35 36 1566 1567 O
history 37 44 1568 1575 O
of 45 47 1576 1578 O
any 48 51 1579 1582 O
other 52 57 1583 1588 O
cancer 58 64 1589 1595 O
( 65 66 1596 1597 O
except 66 72 1597 1603 O
nonmelanoma 73 84 1604 1615 B-cancer
skin 85 89 1616 1620 I-cancer
cancer 90 96 1621 1627 I-cancer
or 97 99 1628 1630 O
carcinoma 100 109 1631 1640 B-cancer
in 110 112 1641 1643 I-cancer
- 112 113 1643 1644 I-cancer
situ 113 117 1644 1648 I-cancer
of 118 120 1649 1651 I-cancer
the 121 124 1652 1655 I-cancer
cervix 125 131 1656 1662 I-cancer
) 131 132 1662 1663 O
, 132 133 1663 1664 O
unless 134 140 1665 1671 O
in 141 143 1672 1674 O
complete 144 152 1675 1683 O
remission 153 162 1684 1693 O
with 163 167 1694 1698 O
no 168 170 1699 1701 O
therapy 171 178 1702 1709 B-treatment
for 179 182 1710 1713 O
a 183 184 1714 1715 O
minimum 185 192 1716 1723 O
of 193 195 1724 1726 O
3 196 197 1727 1728 B-lower_bound
years 198 203 1729 1734 I-lower_bound

Have 0 4 1735 1739 O
initiated 5 14 1740 1749 O
bisphosphonates 15 30 1750 1765 B-treatment

Have 0 4 1766 1770 O
locally 5 12 1771 1778 O
advanced 13 21 1779 1787 B-cancer
disease 22 29 1788 1795 I-cancer
not 30 33 1796 1799 O
amenable 34 42 1800 1808 O
to 43 45 1809 1811 O
curative 46 54 1812 1820 B-treatment
treatment 55 64 1821 1830 I-treatment
by 65 67 1831 1833 O
surgery 68 75 1834 1841 B-treatment
or 76 78 1842 1844 O
metastatic 79 89 1845 1855 B-cancer
disease 90 97 1856 1863 I-cancer

Have 0 4 1864 1868 O
postmenopausal 5 19 1869 1883 O
status 20 26 1884 1890 O
due 27 30 1891 1894 O
to 31 33 1895 1897 O
either 34 40 1898 1904 O
surgical 41 49 1905 1913 O
/ 49 50 1913 1914 O
natural 50 57 1914 1921 O
menopause 58 67 1922 1931 O
or 68 70 1932 1934 O
ovarian 71 78 1935 1942 B-treatment
suppression 79 90 1943 1954 I-treatment
( 91 92 1955 1956 O
initiated 92 101 1956 1965 O
at 102 104 1966 1968 O
least 105 110 1969 1974 O
28 111 113 1975 1977 B-lower_bound
days 114 118 1978 1982 I-lower_bound
prior 119 124 1983 1988 I-lower_bound
to 125 127 1989 1991 O
Day 128 131 1992 1995 O
1 132 133 1996 1997 O
of 134 136 1998 2000 O
Cycle 137 142 2001 2006 O
1 143 144 2007 2008 O
) 144 145 2008 2009 O
with 146 150 2010 2014 O
a 151 152 2015 2016 O
gonadotropin 153 165 2017 2029 O
- 165 166 2029 2030 O
releasing 166 175 2030 2039 O
hormone 176 183 2040 2047 O
( 184 185 2048 2049 O
GnRH 185 189 2049 2053 O
) 189 190 2053 2054 O
agonist 191 198 2055 2062 O
such 199 203 2063 2067 O
as 204 206 2068 2070 O
goserelin 207 216 2071 2080 B-treatment

Have 0 4 2081 2085 O
received 5 13 2086 2094 O
an 14 16 2095 2097 O
autologous 17 27 2098 2108 B-treatment
or 28 30 2109 2111 I-treatment
allogeneic 31 41 2112 2122 I-treatment
stem 42 46 2123 2127 I-treatment
- 46 47 2127 2128 I-treatment
cell 47 51 2128 2132 I-treatment
transplant 52 62 2133 2143 I-treatment

Have 0 4 2144 2148 O
received 5 13 2149 2157 O
prior 14 19 2158 2163 B-treatment
treatment 20 29 2164 2173 I-treatment
with 30 34 2174 2178 I-treatment
chemotherapy 35 47 2179 2191 I-treatment
( 48 49 2192 2193 O
except 49 55 2193 2199 O
for 56 59 2200 2203 O
neoadjuvant/ 60 72 2204 2216 B-treatment
adjuvant 73 81 2217 2225 B-treatment
chemotherapy 82 94 2226 2238 I-treatment
) 94 95 2238 2239 O
, 95 96 2239 2240 O
fulvestrant 97 108 2241 2252 B-treatment
, 108 109 2252 2253 O
everolimus 110 120 2254 2264 B-treatment
, 120 121 2264 2265 O
or 122 124 2266 2268 O
any 125 128 2269 2272 O
CDK4/6 129 135 2273 2279 B-treatment
inhibitor 136 145 2280 2289 I-treatment
. 145 146 2289 2290 O
For 147 150 2291 2294 O
the 151 154 2295 2298 O
endocrine 155 164 2299 2308 O
naïve 165 170 2309 2314 O
cohort 171 177 2315 2321 O
: 177 178 2321 2322 O
In 179 181 2323 2325 O
addition 182 190 2326 2334 O
, 190 191 2334 2335 O
have 192 196 2336 2340 O
received 197 205 2341 2349 O
treatment 206 215 2350 2359 B-treatment
with 216 220 2360 2364 I-treatment
any 221 224 2365 2368 I-treatment
prior 225 230 2369 2374 I-treatment
endocrine 231 240 2375 2384 I-treatment
therapy 241 248 2385 2392 I-treatment

Have 0 4 2393 2397 O
received 5 13 2398 2406 O
recent 14 20 2407 2413 O
( 21 22 2414 2415 O
within 22 28 2415 2421 O
28 29 31 2422 2424 B-upper_bound
days 32 36 2425 2429 I-upper_bound
prior 37 42 2430 2435 I-upper_bound
to 43 45 2436 2438 O
randomization 46 59 2439 2452 O
) 59 60 2452 2453 O
yellow 61 67 2454 2460 B-treatment
fever 68 73 2461 2466 I-treatment
vaccination 74 85 2467 2478 I-treatment

Have 0 4 2479 2483 O
received 5 13 2484 2492 O
treatment 14 23 2493 2502 B-treatment
with 24 28 2503 2507 O
a 29 30 2508 2509 O
drug 31 35 2510 2514 O
that 36 40 2515 2519 O
has 41 44 2520 2523 O
not 45 48 2524 2527 O
received 49 57 2528 2536 O
regulatory 58 68 2537 2547 O
approval 69 77 2548 2556 O
for 78 81 2557 2560 O
any 82 85 2561 2564 O
indication 86 96 2565 2575 O
within 97 103 2576 2582 O
14 104 106 2583 2585 B-lower_bound
or 107 109 2586 2588 O
21 110 112 2589 2591 B-upper_bound
days 113 117 2592 2596 I-upper_bound
prior 118 123 2597 2602 I-upper_bound
to 124 126 2603 2605 O
randomization 127 140 2606 2619 O
of 141 143 2620 2622 O
study 144 149 2623 2628 O
drug 150 154 2629 2633 O
for 155 158 2634 2637 O
a 159 160 2638 2639 O
nonmyelosuppressive 161 180 2640 2659 B-treatment
or 181 183 2660 2662 O
myelosuppressive 184 200 2663 2679 B-treatment
agent 201 206 2680 2685 I-treatment

Have 0 4 2686 2690 O
visceral 5 13 2691 2699 B-chronic_disease
crisis 14 20 2700 2706 I-chronic_disease
, 20 21 2706 2707 O
lymphangitic 22 34 2708 2720 B-chronic_disease
spread 35 41 2721 2727 I-chronic_disease
, 41 42 2727 2728 O
or 43 45 2729 2731 O
leptomeningeal 46 60 2732 2746 B-cancer
carcinomatosis 61 75 2747 2761 I-cancer
visceral 76 84 2762 2770 O
crisis 85 91 2771 2777 O
is 92 94 2778 2780 O
not 95 98 2781 2784 O
the 99 102 2785 2788 O
mere 103 107 2789 2793 O
presence 108 116 2794 2802 O
of 117 119 2803 2805 O
visceral 120 128 2806 2814 B-cancer
metastases 129 139 2815 2825 I-cancer
but 140 143 2826 2829 O
implies 144 151 2830 2837 O
severe 152 158 2838 2844 O
organ 159 164 2845 2850 O
dysfunction 165 176 2851 2862 O
as 177 179 2863 2865 O
assessed 180 188 2866 2874 O
by 189 191 2875 2877 O
symptoms 192 200 2878 2886 O
and 201 204 2887 2890 O
signs 205 210 2891 2896 O
, 210 211 2896 2897 O
laboratory 212 222 2898 2908 O
studies 223 230 2909 2916 O
, 230 231 2916 2917 O
and 232 235 2918 2921 O
rapid 236 241 2922 2927 O
progression 242 253 2928 2939 O
of 254 256 2940 2942 O
the 257 260 2943 2946 O
disease 261 268 2947 2954 O

Participants 0 12 2955 2967 O
may 13 16 2968 2971 O
not 17 20 2972 2975 O
have 21 25 2976 2980 O
received 26 34 2981 2989 O
more 35 39 2990 2994 O
than 40 44 2995 2999 O
1 45 46 3000 3001 B-lower_bound
line 47 51 3002 3006 O
of 52 54 3007 3009 O
endocrine 55 64 3010 3019 B-treatment
therapy 65 72 3020 3027 I-treatment
or 73 75 3028 3030 O
any 76 79 3031 3034 O
prior 80 85 3035 3040 B-treatment
chemotherapy 86 98 3041 3053 I-treatment
for 99 102 3054 3057 O
metastatic 103 113 3058 3068 B-cancer
disease 114 121 3069 3076 I-cancer

approved 0 8 3077 3085 O
Receptor 9 17 3086 3094 O
activator 18 27 3095 3104 O
of 28 30 3105 3107 O
nuclear 31 38 3108 3115 B-treatment
factor 39 45 3116 3122 I-treatment
kappa 46 51 3123 3128 I-treatment
- 51 52 3128 3129 I-treatment
B 52 53 3129 3130 I-treatment
( 54 55 3131 3132 I-treatment
RANK 55 59 3132 3136 I-treatment
) 59 60 3136 3137 I-treatment
ligand 61 67 3138 3144 I-treatment
targeted 68 76 3145 3153 I-treatment
agents 77 83 3154 3160 I-treatment
< 84 85 3161 3162 O
7 85 86 3162 3163 B-upper_bound
days 87 91 3164 3168 I-upper_bound
prior 92 97 3169 3174 I-upper_bound
to 98 100 3175 3177 O
randomization 101 114 3178 3191 O

for 0 3 3192 3195 O
the 4 7 3196 3199 O
endocrine 8 17 3200 3209 O
naïve 18 23 3210 3215 O
cohort 24 30 3216 3222 O
: 30 31 3222 3223 O
Must 32 36 3224 3228 O
not 37 40 3229 3232 O
have 41 45 3233 3237 O
received 46 54 3238 3246 O
prior 55 60 3247 3252 O
endocrine 61 70 3253 3262 B-treatment
therapy 71 78 3263 3270 I-treatment
in 79 81 3271 3273 O
current 82 89 3274 3281 O
or 90 92 3282 3284 O
prior 93 98 3285 3290 O
disease 99 106 3291 3298 O
setting 107 114 3299 3306 O

presented 0 9 3307 3316 O
de 10 12 3317 3319 O
novo 13 17 3320 3324 O
with 18 22 3325 3329 O
metastatic 23 33 3330 3340 B-cancer
disease 34 41 3341 3348 I-cancer
and 42 45 3349 3352 O
then 46 50 3353 3357 O
relapsed 51 59 3358 3366 O
with 60 64 3367 3371 O
radiologic 65 75 3372 3382 O
evidence 76 84 3383 3391 O
of 85 87 3392 3394 O
progression 88 99 3395 3406 O
after 100 105 3407 3412 O
receiving 106 115 3413 3422 O
treatment 116 125 3423 3432 B-treatment
with 126 130 3433 3437 O
either 131 137 3438 3444 O
an 138 140 3445 3447 O
antiestrogen 141 153 3448 3460 B-treatment
or 154 156 3461 3463 O
an 157 159 3464 3466 O
aromatase 160 169 3467 3476 B-treatment
inhibitor 170 179 3477 3486 I-treatment
as 180 182 3487 3489 O
first 183 188 3490 3495 B-treatment
line 189 193 3496 3500 I-treatment
endocrine 194 203 3501 3510 I-treatment
therapy 204 211 3511 3518 I-treatment
for 212 215 3519 3522 O
metastatic 216 226 3523 3533 O
disease 227 234 3534 3541 O

relapsed 0 8 3542 3550 O
with 9 13 3551 3555 O
radiologic 14 24 3556 3566 O
evidence 25 33 3567 3575 O
of 34 36 3576 3578 O
progression 37 48 3579 3590 O
more 49 53 3591 3595 O
than 54 58 3596 3600 O
1 59 60 3601 3602 B-lower_bound
year 61 65 3603 3607 I-lower_bound
from 66 70 3608 3612 O
completion 71 81 3613 3623 O
of 82 84 3624 3626 O
adjuvant 85 93 3627 3635 B-treatment
endocrine 94 103 3636 3645 I-treatment
therapy 104 111 3646 3653 I-treatment
and 112 115 3654 3657 O
then 116 120 3658 3662 O
subsequently 121 133 3663 3675 O
relapsed 134 142 3676 3684 O
with 143 147 3685 3689 O
radiologic 148 158 3690 3700 O
evidence 159 167 3701 3709 O
of 168 170 3710 3712 O
progression 171 182 3713 3724 O
after 183 188 3725 3730 O
receiving 189 198 3731 3740 O
treatment 199 208 3741 3750 B-treatment
with 209 213 3751 3755 I-treatment
either 214 220 3756 3762 I-treatment
an 221 223 3763 3765 I-treatment
antiestrogen 224 236 3766 3778 I-treatment
or 237 239 3779 3781 I-treatment
an 240 242 3782 3784 I-treatment
aromatase 243 252 3785 3794 I-treatment
inhibitor 253 262 3795 3804 I-treatment
as 263 265 3805 3807 I-treatment
first 266 271 3808 3813 I-treatment
- 271 272 3813 3814 I-treatment
line 272 276 3814 3818 I-treatment
endocrine 277 286 3819 3828 I-treatment
therapy 287 294 3829 3836 I-treatment
for 295 298 3837 3840 O
metastatic 299 309 3841 3851 B-cancer
disease 310 317 3852 3859 I-cancer

relapsed 0 8 3860 3868 O
with 9 13 3869 3873 O
radiologic 14 24 3874 3884 O
evidence 25 33 3885 3893 O
of 34 36 3894 3896 O
progression 37 48 3897 3908 O
while 49 54 3909 3914 O
receiving 55 64 3915 3924 O
neoadjuvant 65 76 3925 3936 B-treatment
or 77 79 3937 3939 O
adjuvant 80 88 3940 3948 B-treatment
endocrine 89 98 3949 3958 I-treatment
therapy 99 106 3959 3966 I-treatment
, 106 107 3966 3967 O
with 108 112 3968 3972 O
no 113 115 3973 3975 O
subsequent 116 126 3976 3986 B-treatment
endocrine 127 136 3987 3996 I-treatment
therapy 137 144 3997 4004 I-treatment
received 145 153 4005 4013 O
following 154 163 4014 4023 O
progression 164 175 4024 4035 O

relapsed 0 8 4036 4044 O
with 9 13 4045 4049 O
radiologic 14 24 4050 4060 O
evidence 25 33 4061 4069 O
of 34 36 4070 4072 O
progression 37 48 4073 4084 O
within 49 55 4085 4091 O
1 56 57 4092 4093 B-upper_bound
year 58 62 4094 4098 I-upper_bound
from 63 67 4099 4103 O
completion 68 78 4104 4114 O
of 79 81 4115 4117 O
adjuvant 82 90 4118 4126 B-treatment
endocrine 91 100 4127 4136 I-treatment
therapy 101 108 4137 4144 I-treatment
, 108 109 4144 4145 O
with 110 114 4146 4150 O
no 115 117 4151 4153 O
subsequent 118 128 4154 4164 O
endocrine 129 138 4165 4174 O
therapy 139 146 4175 4182 O
received 147 155 4183 4191 O
following 156 165 4192 4201 O
progression 166 177 4202 4213 O

